

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1-124. (Canceled)

125. (Previously presented) An antisense oligonucleotide 14 to 30 nucleobases in length comprising at least 14 contiguous nucleotides of SEQ ID NO:247.

126. (Previously presented) The antisense oligonucleotide of claim 125, fourteen to twenty nucleobases in length.

127. (Previously presented) The antisense oligonucleotide of claim 125, wherein the antisense oligonucleotide has a sequence comprising SEQ ID NO:247.

128. (Previously presented) The antisense oligonucleotide of claim 125, wherein the antisense oligonucleotide has a sequence consisting of SEQ ID NO:247.

129. (Previously presented) The antisense oligonucleotide of claim 125, wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage.

130. (Previously presented) The antisense oligonucleotide of claim 129, wherein the modified internucleoside linkage is a phosphorothioate linkage.

131. (Previously presented) The antisense oligonucleotide of claim 125, wherein the antisense oligonucleotide comprises at least one modified sugar moiety.

132. (Previously presented) The antisense oligonucleotide of claim 131, wherein the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety.

133. (Previously presented) The antisense oligonucleotide of claim 131, wherein the modified sugar moiety is a bicyclic sugar moiety.

134. (Previously presented) The antisense oligonucleotide of claim 125, wherein the antisense oligonucleotide is a chimeric oligonucleotide having a plurality of 2'-deoxynucleotides flanked on each side by at least one nucleotide having a modified sugar moiety.

135. (Previously presented) The antisense oligonucleotide of claim 134, wherein the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety.
136. (Previously presented) The antisense oligonucleotide of claim 134, wherein the modified sugar moiety is a bicyclic sugar moiety.
137. (Previously presented) The antisense oligonucleotide of claim 125, wherein the antisense oligonucleotide comprises at least one modified nucleobase.
138. (Previously presented) The antisense oligonucleotide of claim 137, wherein the modified nucleobase is a 5-methylcytosine.
139. (Previously presented) The antisense oligonucleotide of claim 125, wherein the antisense oligonucleotide is in a salt form.
140. (Previously presented) The antisense oligonucleotide of claim 139, wherein the antisense oligonucleotide is a sodium salt.
141. (Previously presented) A composition comprising the antisense oligonucleotide of any one of claims 125-140 and a pharmaceutically acceptable carrier or diluent.
142. (Previously presented) An antisense oligonucleotide 20 nucleobases in length having the sequence of nucleobases as set forth in SEQ ID NO:247 and comprising 5-methylcytidine at nucleobases 2, 3, 5, 9, 12, 15, 17, 19, and 20, wherein every internucleoside linkage is a phosphorothioate linkage, nucleobases 1-5 and 16-20 are 2'-O-methoxyethyl nucleotides, and nucleobases 6-15 are 2'-deoxynucleotides.
143. (Previously presented) The antisense oligonucleotide of claim 142, wherein the antisense oligonucleotide is in a salt form.
144. (Previously presented) The antisense oligonucleotide of claim 143, wherein the antisense oligonucleotide is a sodium salt.
145. (Previously presented) A composition comprising the antisense oligonucleotide of any of claims 142 - 144 and a pharmaceutically acceptable carrier or diluent.
- 146-196. (Canceled)

197. (Previously presented) An antisense compound 14 to 30 nucleobases in length and fully complementary to SEQ ID NO:3, wherein said compound is targeted to the range of nucleotides 3230-3287 as set forth in SEQ ID NO:3.
198. (Previously presented) The antisense compound of claim 197, which is 14 to 20 nucleotides in length.
199. (Previously presented) The antisense compound of claim 197, which is an antisense oligonucleotide.
200. (Previously presented) The antisense oligonucleotide of claim 199, wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage.
201. (Previously presented) The antisense oligonucleotide of claim 200, wherein the modified internucleoside linkage is a phosphorothioate linkage.
202. (Previously presented) The antisense oligonucleotide of claim 199, wherein the antisense oligonucleotide comprises at least one modified sugar moiety.
203. (Previously presented) The antisense oligonucleotide of claim 202, wherein the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety.
204. (Previously presented) The antisense oligonucleotide of claim 202, wherein the modified sugar moiety is a bicyclic sugar moiety.
205. (Previously presented) The antisense oligonucleotide of claim 199, wherein the antisense oligonucleotide is a chimeric oligonucleotide having a plurality of 2'-deoxynucleotides flanked on each side by at least one nucleotide having a modified sugar moiety.
206. (Previously presented) The antisense oligonucleotide of claim 205, wherein the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety.
207. (Previously presented) The antisense oligonucleotide of claim 205, wherein the modified sugar moiety is a bicyclic sugar moiety.
208. (Previously presented) The antisense oligonucleotide of claim 199, wherein the antisense oligonucleotide comprises at least one modified nucleobase.

209. (Previously presented) The antisense oligonucleotide of claim 208, wherein the modified nucleobase is a 5-methylcytosine.
210. (Previously presented) The antisense compound of claim 197, wherein the antisense compound is in a salt form.
211. (Previously presented) The antisense compound of claim 210, wherein the antisense compound is a sodium salt.
212. (Previously presented) A composition comprising the antisense compound of any one of claims 197-211 and a pharmaceutically acceptable carrier or diluent.
- 213.-215. (Canceled)